Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY294002 |
| Synonyms | |
| Therapy Description |
LY294002 is a specific inhibitor of PI3K alpha, beta, and delta, which leads to inhibition of PI3K-Akt/PKB signaling (PMID: 12060641, PMID: 31759362, PMID: 31732769). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY294002 | LY-294002|LY 294002|NSC-697286|SF-1101 | PI3K Inhibitor (Pan) 42 | LY294002 is a specific inhibitor of PI3K alpha, beta, and delta, which leads to inhibition of PI3K-Akt/PKB signaling (PMID: 12060641, PMID: 31759362, PMID: 31732769). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA E418K | breast cancer | sensitive | LY294002 | Preclinical - Cell culture | Actionable | In a preclinical study, LY294002 inhibited proliferation of a breast cancer cell line expressing PIK3CA E418K in culture (PMID: 38909932). | 38909932 |
| PIK3CA E545K | esophagus squamous cell carcinoma | sensitive | LY294002 | Preclinical | Actionable | In a preclinical study, LY294002 inhibited cell proliferation of esophagus squamous cell carcinoma cells expressing PIK3CA E545K (PMID: 18262558). | 18262558 |
| PIK3CA E453K | breast cancer | decreased response | LY294002 | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing PIK3CA E453K was less sensitive to LY294002 treatment compared to cells overexpressing wild-type PIK3CA or PIK3CA E418K in culture (PMID: 38909932). | 38909932 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|